NeuroMetrix (NURO) Executes 1:6 Stock Split

NeuroMetrix (NURO) executed a 1:6 stock split before the market opened yesterday. NURO's previous close was $0.48, which adjusted to $2.88. NURO opened at $2.33, down 19.1%. Ouch! NURO recovered to hit an intra-day high of $2.95, but closed at $2.51. NURO's 52-week high is currently $5.28.

NeuroMetrix (NURO) also reported 4Q'12 results. From the press release.

"We enter 2013 with two novel and proprietary diabetes products, a focused commercial plan, and a lower cost operating structure that we can leverage with growth," said Shai N. Gozani, M.D., Ph.D., President and Chief Executive Officer of NeuroMetrix. "We met our financial, product development and commercial goals during 2012. Fiscal 2013 is an important year for the Company. We are optimistic about the market potential for our products and the diabetic neuropathy space in general."